V12 SENTINEL ENGINE · AI MARKET ANALYSIS
Mid
M
MIRMAI Stock Diagnostic Report

Mirum to present phase 3 hepatitis delta study results Monday

Mirum plans to announce Phase 3 study results for its hepatitis B delta virus treatment on Monday, but the stock's direction remains uncertain as the results have not yet been disclosed.

View Source Article ↗
AI CATALYST SCORE50 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time
+
ANALYSIS HISTORY

MIRM Analysis History (Last 30 Days)

Diagnosed AtTickerAI ScoreTier
2026-10-12 14:27:30MIRM85MidView Report →
2026-10-11 21:23:14MIRM35RowView Report →
2026-09-28 15:47:00MIRM45MidView Report →
View Full History for MIRM (Blueprint) →